Abbisko Therapeutics Reports Positive Preliminary Phase 2 Results for Achondroplasia Treatment
Abbisko Therapeutics has announced positive preliminary efficacy results from its Phase 2 clinical study of lavengratinib (ABSK061) for the treatment of achondroplasia.
Chinese drug development company Abbisko Therapeutics has released positive preliminary efficacy results from its ongoing Phase 2 clinical study of lavengratinib (ABSK061). The drug is being investigated for the treatment of achondroplasia, a rare skeletal growth disorder.
The study's preliminary findings indicate lavengratinib's potential to improve clinical features associated with achondroplasia. More detailed information regarding the study's specific outcomes and statistical significance is expected later as the trial progresses and more data is collected.
Achondroplasia is the most common form of dwarfism in humans, caused by a mutation in the fibroblast growth factor receptor 3 (FGFR3) gene. Currently, treatment for the condition is primarily symptomatic, and the development of new effective therapies remains a significant medical need.
According to Abbisko Therapeutics, lavengratinib is a selective small molecule inhibitor that specifically targets the FGFR3 receptor. The company is continuing the study and plans to release further details as the trial progresses.